Insider Selling: Tempus AI, Inc. (NASDAQ:TEM) COO Sells 20,000 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) COO Ryan Fukushima sold 20,000 shares of Tempus AI stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $39.61, for a total value of $792,200.00. Following the completion of the transaction, the chief operating officer now owns 982,442 shares of the company’s stock, valued at $38,914,527.62. This trade represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Ryan Fukushima also recently made the following trade(s):

• On Monday, December 16th, Ryan Fukushima sold 3,500 shares of Tempus AI stock. The stock was sold at an average price of $40.23, for a total value of $140,805.00.
• On Wednesday, December 11th, Ryan Fukushima sold 120,000 shares of Tempus AI stock. The shares were sold at an average price of $42.51, for a total value of $5,101,200.00.

Tempus AI Price Performance

Tempus AI stock opened at $37.49 on Thursday. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $79.49. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. The firm has a 50 day simple moving average of $48.59 and a 200-day simple moving average of $46.96.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on TEM shares. Piper Sandler reiterated a “neutral” rating and set a $70.00 target price (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Bank of America increased their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. Loop Capital lifted their target price on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. Wolfe Research assumed coverage on Tempus AI in a report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target on the stock. Finally, Guggenheim initiated coverage on Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 target price on the stock. Three analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Tempus AI presently has an average rating of “Moderate Buy” and a consensus price target of $56.00.

Hedge Funds Weigh In On Tempus AI

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TEM. Silverleafe Capital Partners LLC acquired a new position in Tempus AI during the fourth quarter worth about $533,000. Franklin Resources Inc. raised its holdings in shares of Tempus AI by 1.0% in the 3rd quarter. Franklin Resources Inc. now owns 811,311 shares of the company’s stock worth $45,920,000 after purchasing an additional 8,387 shares in the last quarter. Tidal Investments LLC acquired a new stake in Tempus AI during the third quarter valued at approximately $7,633,000. Teachers Retirement System of The State of Kentucky boosted its holdings in Tempus AI by 6.3% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 126,500 shares of the company’s stock worth $7,160,000 after buying an additional 7,500 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Tempus AI by 0.4% in the third quarter. Geode Capital Management LLC now owns 133,171 shares of the company’s stock worth $7,537,000 after buying an additional 539 shares during the last quarter. 24.22% of the stock is owned by institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.